Anesthesia type and lung cancer recurrence after curative surgery

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This double-blind, randomized, multicenter trial assigns adults undergoing curative-intent lung resection for non-small cell lung cancer 1:1 to receive either propofol-based total intravenous anesthesia (TIVA) or volatile inhaled anesthetics. Enrollment is planned across 22 international sites with centralized web-based randomization and data capture, and standard perioperative care is otherwise left to treating teams. The primary outcome is recurrence-free survival after surgery, with longitudinal follow-up for cancer recurrence. The trial is pragmatic and does not standardize perioperative management beyond the randomized anesthesia strategy.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* American Society of Anesthesiologists physical status (ASA) Ⅰ-Ⅲ
* The Eastern Cooperative Oncology Group (ECOG) performance status 0-2
* Lung resection surgery (segmentectomy, lobectomy, bilobectomy, pneumonectomy; video-assisted, robot-assisted, or open) with curative intent for NSCLC (clinical Tumor, Node, Metastasis (TNM) stage Ⅰ- ⅢA).

Exclusion Criteria:

* Distant metastasis or malignant tumor in other organs that according to the attending surgeon is not in long-term remission
* Severe neurologic conditions
* Severe hepatic disease (Child-Pugh classification C)
* Renal failure requiring renal replacement therapy
* History of anesthesia and/or surgery within 1 yr
* Previous surgery due to lung cancer (except diagnostic biopsies)
* Contraindications to any study medication (history of allergy, hypersensitivity reaction, or any other contraindication)
* Planned joint extrapulmonary procedure
* Surgery under cardiopulmonary bypass or extracorporeal membrane oxygenation
* Postoperative sedation
* Pregnancy, or lactation
* Patient refusal.

Where it's running

• Samsung Medical Center
  Seoul, Seoul-teukbyeolsi, South Korea Recruiting

Study contacts

• Principal investigator: Hyun Joo Ahn — Department of Anesthesiology and Pain Medicine, Samsung Medical Center
• Study coordinator: Jeayoun Kim, MD
• Email: jeayoun.kim@samsung.com
• Phone: 8234106590

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Patient-specific MRD liquid biopsy for resected NSCLC

  This study tests a personalized MRD blood and bronchial washing test after surgery to see if it can signal recurrence earlier in people with resected NSCLC.

  Recruiting Yonsei University · Yongin-si, Gyeonggi-do and 2 other locations · NCT07921888

• Osimertinib Plus SRS/SRT for EGFR-Mutant NSCLC with Symptomatic Brain Metastases

  This study tests whether adding targeted brain radiotherapy to osimertinib helps control brain metastases in adults with EGFR-mutant NSCLC and neurological symptoms.

  Recruiting Phase 2 Cho Ray Hospital · Ho Chi Minh City · NCT07911449

• Dato-DXd in solid tumors (Urothelial Cancer and KRAS-mutant NSCLC) in two sub-studies

  This study tests Datopotamab Deruxtecan (Dato-DXd) alone or with other cancer drugs in people with urothelial cancer or KRAS-mutant non-small cell lung cancer.

  Recruiting Phase 1/2 Daiichi Sankyo · Taichung · NCT07890714

• SI-B036 safety test in advanced and metastatic solid tumors

  This early-phase study checks whether SI-B036 is safe and tolerable in adults with advanced or metastatic solid cancers who have had prior therapy.

  Recruiting at 4 sites Phase 1 SystImmune Inc. · New Haven, Connecticut and 6 other locations · NCT07857616

• Postoperative EGFR-TKI Therapy for EGFR-mutant NSCLC Following Surgery

  This registry tests whether giving an EGFR-TKI after surgery helps adults with EGFR-mutant, high-risk early-stage NSCLC.

  Recruiting Tongji Hospital · Wuhan, Hubei · NCT07837739

• HS-20093 with Adebrelimab vs HS-20093 alone in advanced non-squamous NSCLC

  This study tests whether adding adebrelimab to HS-20093 helps patients with advanced non-squamous NSCLC who have already had treatment.

  Recruiting Phase 2 Hansoh BioMedical R&D Company · Wuhan, Hubei · NCT07824882

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.